Drugs / ALT-L9
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04058535 | Feb → Dec 2020 | wet macular degeneration | Alteogen, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALT-L9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04058535 ↗ |
| Route | Intravitreal | “Intravitreal injection of ALT-L9 50 ul, every 4 weeks” NCT04058535 ↗ |